Blood-based Biomarkers for Diagnosis of Alzheimer's

Summary

Alzheimer's disease (AD) may currently be diagnosed using molecular biomarkers in cerebrospinal fluid (CSF) and/or positron emission tomography (PET). These diagnostic procedures are highly accurate, but the high cost and low availability hamper their feasibility. Recently, ultrasensitive blood tests predicting Alzheimer pathologies in the brain have been developed. These tests have a reliable ability to differentiate AD from other neurodegenerative disorders and identify AD across the clinical continuum with high sensitivity and specificity in research cohorts with a high prevalence of AD. This project will assess the predictive value of these tests in a general practice population. The hypothesis is that the actual blood panel will have high positive predictive value for a diagnosis of Alzheimer's disease in the primary health care setting.

Interventions

• predictive value of a blood test · DIAGNOSTIC_TEST

  Evaluation of the clinical value of a new blood based test for diagnosis of Alzheimer's disease in a general practice population.

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* Participants suspected by their GP to have possible dementia, based on history, clinical examination and/or cognitive screening

Exclusion Criteria:

* Lack of capacity for consent as judged by the GP.
* Severe psychiatric disease, use of medication or physical disease that according to the GP may affect participation or likely contribute significantly to the observed cognitive impairment.
* Patients not wanting to be referred to the memory outpatient clinic.

Sites (1)

• Stavanger University Hospital, Stavanger, Norway · RECRUITING